📋
What this means for you
AI-generated plain English summary
✓
# What You Need to Know About This Medicine
✓
What this means**: The health authorities stopped reviewing a new cancer treatment called lisocabtagene maraleucel that was being developed to help people with a type of blood cancer (follicular lymphoma) that hasn't responded to at least 2 previous treatments—this means the medicine won't be available through this particular approval process.
✓
What you should do**: If you have follicular lymphoma that hasn't worked with other treatments, talk to your doctor about other available options; this stopped review doesn't mean there are no treatments for you, just that this particular one won't go through this approval pathway.
✓
Key takeaway**: Don't worry if you're currently being treated—this is about a new medicine review process that ended, not about stopping any treatment you're already receiving.
Always speak to your doctor before making any changes to your health or treatment.
New Guidance: NICE
View official guidance ↗
View official guidance ↗
TA1186
📋 What this means for you: Speak to your GP or specialist to understand how this guidance affects your care.
Read full article on NICE ↗
This article summarises content originally published by NICE. PatientIQ provides independent plain English summaries.
More Cancer News
BBC Health
BBC Health
NICE
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer…
10 Sep 2026
Very hot drinks may damage the food pipe and increase cancer risk
09 Sep 2026
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent…
09 Sep 2026